国家癌症数据库分析:质子与光子放疗在非小细胞肺癌中的比较
基于国家癌症数据库2004至2012年243822例I-IV期非小细胞肺癌患者,比较质子与光子胸部放疗的生存结局。多因素分析显示非质子治疗与更差生存相关(HR 1.21,95%CI 1.06-1.39,P<.01)。倾向匹配分析中质子治疗5年总生存为22%对16%(P=.025),但需随机研究验证。
要点
- 质子治疗与更好生存相关,但为回顾性分析,需随机验证。
- 倾向匹配后质子治疗5年总生存22% vs 16%(P=.025)。
- II-III期患者非质子治疗生存更差(HR 1.35,95%CI 1.10-1.64)。
核心结论
- 回顾性分析中质子胸部放疗与更好生存相关,需随机研究验证。
研究设计与样本
- 查询国家癌症数据库,纳入2004至2012年接受胸部放疗的I-IV期NSCLC患者243822例,其中光子243474例、质子348例。
- 采用逻辑回归分析质子治疗使用预测因素,Cox比例风险模型和log-rank检验评估总生存,并行倾向评分匹配。
主要发现
- 全人群多因素分析中非质子治疗与更差生存相关(HR 1.21,95%CI 1.06-1.39;P<.01)。
- 倾向匹配分析中质子治疗(n=309)5年总生存22%,非质子治疗(n=1549)为16%(P=.025)。
- II和III期患者中非质子治疗与更差生存相关(HR 1.35,95%CI 1.10-1.64,P<.01)。
关键数值与推荐
- 邮政编码区域年收入中位数低于46000美元的患者接受质子治疗可能性更低。
- 收入30000至35999美元组接受质子治疗可能性最低(OR 0.63,95%CI 0.44-0.90;P=.011)。
临床怎么用
- 结果为回顾性关联,不能据此常规推荐质子治疗优于光子放疗。
- 质子治疗选择需考虑经济可及性差异,并等待随机研究验证。
局限性
- 为回顾性分析,需随机研究验证以排除患者特征(包括PET-CT分期)的不平衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To analyze outcomes and predictors associated with proton radiation therapy for non-small cell lung cancer (NSCLC) in the National Cancer Database. METHODS AND MATERIALS: The National Cancer Database was queried to capture patients with stage I-IV NSCLC treated with thoracic radiation from 2004 to 2012. A logistic regression model was used to determine the predictors for utilization of proton radiation therapy. The univariate and multivariable association with overall survival were assessed by Cox proportional hazards models along with log-rank tests. A propensity score matching method was implemented to balance baseline covariates and eliminate selection bias. RESULTS: A total of 243,822 patients (photon radiation therapy: 243,474; proton radiation therapy: 348) were included in the analysis. Patients in a ZIP code with a median income of <$46,000 per year were less likely to receive proton treatment, with the income cohort of $30,000 to $35,999 least likely to receive proton therapy (odds ratio 0.63 [95% confidence interval (CI) 0.44-0.90]; P=.011). On multivariate analysis of all patients, non-proton therapy was associated with significantly worse survival compared with proton therapy (hazard ratio 1.21 [95% CI 1.06-1.39]; P<.01). On propensity matched analysis, proton radiation therapy (n=309) was associated with better 5-year overall survival compared with non-proton radiation therapy (n=1549), 22% versus 16% (P=.025). For stage II and III patients, non-proton radiation therapy was associated with worse survival compared with proton radiation therapy (hazard ratio 1.35 [95% CI 1.10-1.64], P<.01). CONCLUSIONS: Thoracic radiation with protons is associated with better survival in this retrospective analysis; further validation in the randomized setting is needed to account for any imbalances in patient characteristics, including positron emission tomography-computed tomography staging.
引用
- Higgins KA, O'Connell K, Liu Y, et al. National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2016. PMID: 27979443. doi:10.1016/j.ijrobp.2016.10.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。